Prof. Christopher Evans
(29 June 2018)
A survey about the role of imaging and biomarkers in the diagnosis of prostate cancer has been sent to healthcare professionals interested in prostate cancer worldwide.
The results highlighted that healthcare professionals (76% urologists) are more familiar with multiparametric MRI and use it the most. The clinical data on diagnostic biomarkers are less known. This limits the usage of diagnostic biomarkers in daily practice; 42% of urologists completing the survey have never used a biomarker test.
Prof. Evans commented that the cost-effectiveness of biomarkers is also important in this respect. Some of the newer biomarker tests (e.g. SelectMDx) have proven to be cost-effective.
Keen to see the main outcomes of the survey ? Download the slides!